FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Glaxo Group Limited
Glaxo Group Limited A Corporation

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Glaxo Group Limited patents


      
Recent patent applications related to Glaxo Group Limited. Glaxo Group Limited is listed as an Agent/Assignee. Note: Glaxo Group Limited may have other listings under different names/spellings. We're not affiliated with Glaxo Group Limited, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxo Group Limited-related inventors


Search recent Press Releases: Glaxo Group Limited-related press releases
Count Application # Date Glaxo Group Limited patents (updated weekly) - BOOKMARK this page
12015010817804/23/15Re-sealable container
22015010538704/16/15Substituted diketopiperazines and their use as oxytocin antagonists
32015009975604/09/15Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
42015009341404/02/15Modified antigens
52015009344004/02/15Aggregate nanoparticulate medicament formulations, manufacture and use thereof
62015008034303/19/15Benzofuran compounds for the treatment of hepatitis c virus infections
72015008036903/19/15Novel compounds
82015006420103/05/15Antigen binding proteins to oncostatin m (osm)
92015006550703/05/15Novel compounds
102015004537502/12/15Novel compounds
112015000410501/01/15Novel composition
122014037848712/25/14Tricyclic compounds, preparation methods, and their uses
132014037126412/18/14Muscarinic acetylcholine receptor antagonists
142014033508311/13/14Methods of treatment and prevention of eye diseases
152014031197710/23/14Use of organic solvent nanofiltration and liquid-liquid chromatography for the recovery of pharmaceutical products
162014028813309/25/143 -amino- pyrazole derivatives useful against tuberculosis
172014022725908/14/14Modified proteins and peptides
182014022726408/14/14Drug fusions and conjugates with extended half life
192014020560407/24/14Antigen binding constructs
202014020566107/24/14Formulation for retinoid-containing soft gelatin capsules
212014020021807/17/14Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
222014019340707/10/14Drug fusions and conjugates
232014018775007/03/14Methods for selecting protease resistant polypeptides
242014017971506/26/142,3-dihydroimidazo[1 ,2-c] pyrimidin-5(1 h)-one compounds use as lp-pla2 inhibitors
252014015870406/12/14Medicament dispenser
262014014099605/22/14Anti-serum albumin biding variable domains
272014011643405/01/14Dry powder inhaler compositions
282014011292904/24/14Tumour necrosis factor receptor 1 antagonists
292014011388804/24/14Novel combination of therapeutic agents
302014011392204/24/14Compounds
312014010589404/17/14Humanized anti-il-18 antibodies
322014010591504/17/14Bcma (cd269/tnfrsf17) - binding proteins
332014007631403/20/14Manifold for use in medicament dispenser
342014008086303/20/14Muscarinic acetylcholine receptor antagonists
352014005690002/27/14Method for inhibiting binding to b-cell receptor
362014005810502/27/14Substituted diketopiperazines and their use as oxytocin antagonists
372014005071902/20/14Antibodies
382014005172002/20/14N-cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists
392014003898902/06/14Tetrahydropyrazolo [1,5-a] pyrimidine as anti-tuberculosis compounds
402014002359601/23/14Novel composition
412014002455801/23/14Method of treatment
422014000517701/02/14Pyridinyl- and pyrazinyl-methyloxy-aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk)
432014000518801/02/14Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
442013034546512/26/13Process for the preparation of retigabine
452013033698912/19/13Methods of identifying a patient population
462013031590111/28/13Novel uses
472013031704111/28/13Compounds
482013031028111/21/13Novel antigen binding proteins
492013030233511/14/13Ligands that bind tgf-beta receptor ii
502013026771710/10/13Process for the preparation of atovaquone
512013026118510/03/13Benzamide derivatives as ep4 receptor agonists
522013025172409/26/13Antigen binding proteins to oncostatin m (osm)
532013025318809/26/13Novel compounds
542013023750109/12/13Benzofuran compounds for the treatment of hepatitis c virus infections
552013022420408/29/13Method of treatment based on atad2 inhibitors
562013021315408/22/13Method of determining cleanliness
572013021339408/22/13Dispensing device
582013021765808/22/13Pyrazole compounds acting against allergic, inflammatory and immune disorders
592013021089208/15/13Method of treatment
602013020370508/08/13Pyrazole compounds acting against allergic, immune and inflammatory conditions
612013020380208/08/133 -amino- pyrazole derivatives useful against tuberculosis
622013019641208/01/13Magi polynucleotides, polypetides, and antibodies
632013018925507/25/13Fusions and conjugates of insulinotropic agents
642013013133805/23/13Substituted diketopiperazines as oxytocin antagonists
652013011813205/16/13Machine and pharmaceutical and pharmaceutical-like product assembly
662013010969005/02/13Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
672013010278304/25/13Substituted diketopiperazines and their use as oxytocin antagonists
682013007819803/28/13Novel use
692013005337502/28/13Amino-quinolines as kinase inhibitors
702013003947002/14/13Sample plate for an x-ray powder diffraction apparatus
712013004098402/14/137-(lh-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
722013003001201/31/13Compounds
732013003001501/31/13Muscarinic acetylcholine receptor antagonists
742013002354101/24/13Voltage-gated sodium channel blockers
752013001249101/10/13Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
762012031620212/13/12Compounds which have activity at m1 receptor and their uses in medicine
772012030972512/06/12Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
782012030978912/06/12Compounds which have activity at m1 receptor and their uses in medicine
792012028854411/15/12Novel retigabine composition
802012027727911/01/12Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions
812012025146810/04/12Compositions comprising alginates with high guluronic acid/mannuronic acid ratio for use in the treatment of dentine hypersensitivity
822012024074209/27/12Novel device
832012024517109/27/12Benzpyrazole derivatives as inhibitors of pi3 kinases
842012023855909/20/12Novel compounds
852012023857109/20/12Indazole derivatives as pi 3-kinase
862012023206109/13/12Novel compounds
872012020774908/16/12Dosing regimen
882012020281108/09/12Novel compounds
892012015744606/21/12Medical use
902012015749106/21/12Muscarinic acetylcholine receptor antagonists
912012015749206/21/12Antibiotic drug
922012014971106/14/12Piperidine derivatives used as orexin antagonists
932012014973106/14/12New medical use
942012012868905/24/12Anti-il-23 immunoglobulins
952012012977805/24/12Ligand that bind tgf-beta receptor rii
962012011464705/10/12Anti-serum album single variable domains
972012010013704/26/12Immunoglobulins
982012010108304/26/12S1p1 agonists comprising a bicyclic n-containing ring
992012010108604/26/12Thiadiazole derivatives and their use for the treatment of disorders mediated by s1p1 receptors
1002012010112404/26/121,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists
1012012010113404/26/125-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
1022012010113604/26/125-membered heteroaryl derivatives used as sphingosine 1- phosphate receptor agonists
1032012006517703/15/12Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
1042012005896303/08/12Macrolides with anti-inflammatory activity
1052012004625802/23/12Novel crystalline pharmaceutical product
1062012004646902/23/12Process for the preparation of a biphenyl-2-yl carbamic acid ester
1072012003982002/16/12Antibacterial composition comprising 4-isopropyl-3-methylphenol and zinc ions
1082012004099102/16/123-azabicyclo [4.1.0] heptanes used as orexin antagonists
1092012004102702/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
1102012004102802/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
1112012003431202/09/124-isopropyl-3-methylphenol for the treatment of inflammation
1122012000632201/12/12Drug dispenser
1132012000422901/05/12Substituted diketopiperazines and their use as oxytocin antagonists
1142011031937112/29/11Pharmaceutical formulations comprising 4-hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
1152011030569212/15/11Antigen-binding contructs
1162011030569312/15/11Anitigen-binding constructs
1172011028809811/24/11Novel compounds
1182011028190911/17/11Substituted quinoline derivatives as h1 receptor antagonists
1192011027565511/10/11Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
1202011027566111/10/11Tricyclic nitrogen compounds used as antibacterials
1212011026973811/03/11Compounds
1222011026997011/03/11Phenethanolamine derivatives for treatment of respiratory diseases
1232011026358810/27/11Tricyclic compounds as glutamate receptor modulators
1242011025375210/20/11Nozzle for a nasal inhaler
1252011025607410/20/11Novel use
1262011024547010/06/11Immunoglobulins
1272011023779209/29/11Quinoline derivatives and their use as 5-ht6 ligands
1282011019027408/04/11Salt of, and processes for the preparation of, 1-isopropyl-4-hexahydro-1h-1,4-diazepine
1292011017806307/21/11Benzpyrazol derivatives as inhibitors of pi3 kinases
1302011016615007/07/11Anhydrous crystal form of ovrepitant maleate
1312011015087106/23/11Treatment of an autoimmune disease using il-18 antagonists
1322011015226206/23/11Novel compounds
1332011014282406/16/11Antibodies against amyloid-beta peptide
1342011014415106/16/11Novel process, salts, composition and use
1352011013569506/09/11Oral dosage form for controlled drug release
1362011013042306/02/11Compounds which have activity at m1 receptor and their uses in medicine
1372011011719005/19/11Pharmaceutical formulations
1382011011826105/19/11Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
1392011006164603/17/11Drug dispenser
1402011006474003/17/11Antigen binding proteins
1412011006572503/17/11Triazole amide derivatives for use in therapy
1422011005916703/10/11Encapsulation of biologically active agents
1432011005997903/10/11Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators
1442011004502702/24/11Adjuvant
1452011004613702/24/11Pyrazole derivatives as p2x7 modulators
1462011003452402/10/11Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor
1472011002157801/27/11Compounds which potentiate the ampa receptor and uses thereof in medicine
1482011000939401/13/11Tricyclic nitrogen compounds and their use as antibacterial agents
1492011000963101/13/11Phenethanolamine derivatives for treatment of respiratory diseases
1502010032999612/30/10Novel combination of therapeutic agents
1512010032402212/23/10Novel compounds
1522010031657912/16/10Novel use of alkyl phosphate esters
1532010031766612/16/10Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss
1542010031767212/16/10Monomaleate monohydrate salt of a 5ht1a receptor antagonist
1552010030808212/09/10Dispensing device
1562010031170612/09/10Method of treatment of allergic rhinitis
1572010031173412/09/10Spiro compounds useful as antagonists of the h1 receptor
1582010030382112/02/10Immunoglobulins
1592010030510712/02/10Quinoline derivatives and their use as 5-ht6 ligands
1602010030512712/02/10Novel compounds
1612010030516612/02/10Novel compounds
1622010029222411/18/10Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators
1632010029229511/18/105-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
1642010028615211/11/10N-phenyl hydrazides as modulators of the ghrelin receptor
1652010027590911/04/10Actuator for an inhaler
1662010027385310/28/10Novel isoindol derivatives as ep4 receptor agonists
1672010026769110/21/10Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
1682010026773410/21/10N-[(3,5-dichlorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-(1-naphthalenyl)ethanamide as ghrelin receptor modulator
1692010025619910/07/10Crystalline form of an antimalarial compound
1702010025691910/07/10Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
1712010023966609/23/10Process for producing mouldings from (meth) acrylate copolymers by means of injection moulding
1722010022418509/09/10Actuator for an inhaler
1732010022234909/02/10Quinoline derivatives used to treat inflammatory and allergic diseases
1742010021679908/26/10Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists
1752010021683708/26/10Glycine transport inhibitors
1762010021067208/19/10Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
1772010020325608/12/10Method and the application of powder material to substrates
1782010020424208/12/10Piperazine derivative having affinity for the histamine h3 receptor
1792010020427308/12/10Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
1802010019767908/05/10Compounds
1812010019769908/05/10I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders
1822010019076407/29/10Novel compounds
1832010018477007/22/10Compounds
1842010018499607/22/10Process of amide formation
1852010017569807/15/10Capsule
1862010017406507/08/10Compounds
1872010014809106/17/10Method and system for rapid phase luminescense spectroscopy analysis
1882010015219506/17/10Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
1892010014401606/10/10Apparatus for the disruption of animal cells
1902010014475506/10/10Novel compounds
1912010014482906/10/10Novel receptor antagonists and their methods of use
1922010014504006/10/10Benzazepine derivatives for the treatment of neurological disorders
1932010013727606/03/10Compounds which potentiate ampa receptor and uses thereof in medicine
1942010013735306/03/10Tricyclic compounds as antibacterials
1952010013737806/03/10Pyridine compounds for the treatment of prostaglandin mediated diseases
1962010013742806/03/10Oxygen containing heterocycles as glycine transporter inhibiting compounds
1972010013058305/27/10Prolinamide derivatives as modulators of voltage-gated sodium channels
1982010011352105/06/10Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenylpiperidin-3s-yl-)
1992010011352805/06/10Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
2002010011379605/06/10Indole derivatives as s1p1 receptor
2012010010565204/29/10Purines as cysteine protease inhibitors
2022010010568804/29/10Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
2032010010575404/29/105-(4phenyl)prolinamide for treatment of epilepsy
2042010008742404/08/10Tricyclic nitrogen containing heterocycles as antibacterial agents
2052010008750204/08/10Indazoles used to treat estrogen receptor beta mediated disorders
2062010008766704/08/10Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
2072010008183004/01/10Methods of synthesizing n-hydroxysuccinimidyl carbonates
2082010007595303/25/10Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
2092010007598203/25/10Pyridinone derivative for the treatment of premature ejaculation
2102010006816603/18/10Oral composition comprising dimethicone copolyol
2112010006940903/18/10"novel compounds"
2122010006941603/18/10Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine d3 receptors
2132010005905203/11/10Sheet driver for use in a drug dispenser
2142010006309703/11/10Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine d3 receptors
2152010005650203/04/10Compounds
2162010005652703/04/10Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
2172010005659503/04/10Pyrazole derivatives as p2x7 modulators
2182010004863902/25/10Oxadiazole derivates as s1p1 receptor agonists
2192010004167202/18/10Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
2202010002969902/04/10Matrix metalloproteinase inhibitors
2212010001628701/21/10Compounds having affinity for dopamine d3 receptor and uses thereof"
2222010001637101/21/10Indole compounds
2232010001002101/14/10Novel compounds
2242010000052801/07/10Manifold for use in medicament dispenser
2252010000052901/07/10Manifold for use in medicament dispenser
2262010000342001/07/10Medicament dispenser
2272010000423001/07/10Azatricyclic compounds and their use
2282010000424001/07/10Indole compounds
2292009032595212/31/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2302009032603212/31/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2312009031849412/24/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2322009031852312/24/09Benzoisoindole derivatives and their use as ep4 receptor agonists
2332009031853012/24/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2342009031238812/17/09Benzo [f] isoindoles as ep4 receptor agonists
2352009031254612/17/09Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
2362009030605212/10/09Indenyl derivatives and use thereof for the treatment of neurological disorders
2372009029874212/03/09Process for manufacturing lactose
2382009029114611/26/09Process for manufacturing lactose
2392009029198711/26/09Novel polymorph of (5-amino-6-methoxy-3-pyridincarbonyl) carbamic acid 2-(s)-hydroxymutilin 14-ester
2402009028676211/19/09Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
2412009027560411/05/09M3 muscarinic acetylcholine receptor antagonists
2422009027035510/29/09Compounds
2432009027051010/29/09Glycine transport inhibitors
2442009025390810/08/09Novel m3 muscarinic acetylchoine receptor antagonists
2452009023644509/24/09Fluid dispenser
2462009023984609/24/09Novel compounds
2472009023284709/17/09Immunogenic compositions
2482009022754709/10/09Novel salt form of a beta2-adrenergic agonist quinolin-2-one derivative
2492009022762909/10/09Compounds having activity at the glycine transporter glyt1 and uses thereof



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxo Group Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxo Group Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE